Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 439-444

  Ono, Akira ^a   Naito, Tateaki ^a   Ito, Ichiro ^a   Watanabe, Reiko ^a   Shukuya, Takehito ^a   Kenmotsu, Hirotsugu ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Murakami, Haruyasu ^a   Kaira, Kyoichi ^a   Takahashi, Toshiaki ^a   Kameya, Toru ^a   Nakajima, Takashi ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Neuron specific enolase; ProGRP; Small cell lung cancer; Tumor burden; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; ROC CURVE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84862817616     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.012     Document Type: Article

References (30)

1. Jackman D.M., Johnson B.E. Small-cell lung cancer. Lancet 2005, 366:1385-1396.
2. Johnson B.E., Crawford J., Downey R.J., Ettinger D.S., Fossella F., Grecula J.C., et al. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2006, 4:602-622.
3. Akoun G.M., Scarna H.M., Milleron B.J., Bénichou M.P., Herman D.P. Serum neuron-specific enolase - a marker for disease extent and response to therapy for small-cell lung cancer. Chest 1985, 87:39-43.
4. Nõu E., Steinholtz L., Bergh J., Nilsson K., Påhlman S. Neuron-specific enolase as a follow-up, marker in small cell bronchial carcinoma. Cancer 1990, 65:1380-1385.
5. Holst J.J., Hansen M., Bor K.E., Schwartz T.W. Elevated plasma concentrations of c-flanking gastrin-releasing peptide in small-cell lung carcinoma. J Clin Oncol 1989, 7:1831-1838.
6. Moody T.W., Pert C.B., Gazder A.F., Camey D.N., Minna J.D. High level of intraceller bombesin characterize human small-cell lung carcinoma. Science 1981, 214:1246-1248.
7. Yamaguchi K., Abe K., Adachi I., Ostubo K., Nagasaki K., Suzuki M., et al. Peptide hormone production in small cell lung carcinomas with particular reference to gastrin-releasing peptide. Jpn J Clin Oncol 1986, 16:235-241.
8. Wójcik E., Kulpa J.K., Sas-korczyńska, Korzeniowski S., Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small-cell lung cancer. Anticancer Res 2008, 28:3027-3034.
9. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008, 14(23):7813-7821.
10. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
11. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
12. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
13. Shibayama T., Ueoka H., Nishii K., Kiura K., Tabata M., Miyatake K., et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001, 32(1):61-69.
14. Niho S., Nishiwaki Y., Goto K., Ohmatsu H., Matsumoto T., Hojo F., et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000, 27(3):159-167.
15. Nitta T., Fukuoka M., Masuda N., Kusunoki Y., Matsui K., Kudoh S., et al. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Jpn J Clin Oncol 1995, 25:179-183.
16. Hirose T., Okuda K., Yamaoka T., Ishida K., Kusumoto S., Sugiyama T., et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?. Lung Cancer 2011, 71:224-228.
17. Yamaguchi K., Aoyagi K., Urakami K., Fukutani T., Maki N., Yamamoto S., et al. Pro-gastrin-releasing peptide ELISA in clinics for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995, 86:698-705.
18. Toner G.C., Geller N.L., Tan C., Nisselbaum J., Bosl G.J. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990, 50:5904-5910.
19. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 1997, 15:594-603. International Germ Cell Cancer Collaborative Group.
20. Fizazi K., Culine S., Kramar A., Amato R.J., Bouzy J., Chen I., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004, 22:3868-3876.
21. Gogas H., Lofts F.J., Evans T.R., Daryanani S., Mansi J.L. Are serial measurements of CA-19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?. Br J Cancer 1998, 77:325-328.
22. Riedinger J.M., Bonnetain F., Basuyau J.P., Eche N., Larbre H., Dalifard I., et al. Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007, 18:881-885.
23. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008, 26:1148-1159.
24. Vollmer R.T., Govindan R., Graziano S.L., Gamble G., Garst J., Kelley M.J., et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003, 9:1728-1733.
25. Ardizzoni A., Cafferata M.A., Tiseo M., Filiberti R., Marroni P., Grossi F., et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non-small cell lung cancer. Cancer 2006, 107:2842-2849.
26. Chan S.L., Mo F.K., Mok T.S., Hui E.P., Ma B.B., Ho W.M., et al. Serial alpha-fetoprotein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. Proc Am Soc Clin Oncol 2008, 26:238s. (abstract 4602).
27. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I study Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
28. Cuttitta F., Fedorko J., Gu J.A., Lebacq-Verheyden A.M., Linnoila R.I., Battey J.F. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endorcinol Metab 1988, 67:576-583.
29. Ariyoshi Y., Kato K., Ueda R., Takahashi T., Sato T., Akatsuka H., et al. Biological and clinical implication of neuron-specific enolase and creatine kinase BB in small-cell lung cancer. Jpn J Clin Oncol 1986, 16:213-221.
30. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillans, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.